Nouscom

Enhancing cancer-specific cellular immunity with a proprietary portfolio of recombinant viral vectors, that redirect and potentiate anti-tumor cellular immunity to focus on selected immunogenic tumor neoantigens.

The 2014 West African Ebola outbreak caused over 11,000 deaths, prompting efforts to develop an effective vaccine.

The NOUS-209 genetic vaccine for shared cancer neoantigens proved safe and triggered a strong immune response in healthy Lynch syndrome patients.

Nouscom appointed Dr. Marina Udier Blagovic as Chief Operating Officer to oversee business operations and development.

Nouscom secured €12 million in Series A financing in 2016 to advance personalized cancer vaccines and tumor-selective oncolytic viruses.

Nouscom completed a €42 million Series B financing in 2017, led by Abingworth, to support neoantigen cancer vaccine development.

The World Vaccine Congress has grown to become the largest and most established vaccine meeting of its kind across the globe.

Alfredo was previously a co-founder and Chief Scientific Officer of Okairos, leading preclinical and clinical development of several vaccines.

Antonella was a co-founder of Okairos and served as the company’s Director of Immunology. where she contributed to the preclinical and clinical validation of vaccine programs.

John has over 25 years of business development experience with some of the industry’s premier companies.

Marina joined Nouscom in 2016 from Versant Ventures. She received her Ph.D. in Organic Chemistry from Yale University.

The company develops neoantigen and oncolytic-based vaccines using its genetic vaccine expertise.

Nouscom operates offices in Basel and Rome and provides contact information via a form on its website.

Nouscom is a next-generation immunotherapy company developing genetic cancer vaccines and oncolytic viruses..